Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(94 produtos)
- CDK(500 produtos)
- Ciclo celular/Parada(4 produtos)
- Chk(42 produtos)
- DYRK(48 produtos)
- Dinamina(23 produtos)
- Ferroptose(215 produtos)
- HSP(169 produtos)
- Integrinas(224 produtos)
- Cinesina(66 produtos)
- LIM Quinase(19 produtos)
- Microtúbulo associado(261 produtos)
- PKC(102 produtos)
- PLK(28 produtos)
- ROCK(70 produtos)
- Rho(2 produtos)
- Wee1(15 produtos)
- c-Myc(69 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3477 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Polθ-IN-7
CAS:<p>Polθ-IN-7 (example 12) is an inhibitor of DNA polymerase θ (Polθ) with a Ki of 1.27 nM.</p>Fórmula:C28H35F3N6O2Cor e Forma:SolidPeso molecular:544.612Cdc7-IN-10
CAS:<p>Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.</p>Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48CDK7-IN-33
CAS:<p>CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.</p>Fórmula:C29H36N6O4SCor e Forma:SolidPeso molecular:564.699DHX9-IN-19
CAS:<p>DHX9-IN-19 (compound 3) is an orally active inhibitor of DHX9, playing a significant role in cancer research.</p>Fórmula:C20H21ClN4O4S2Cor e Forma:SolidPeso molecular:480.988IRE1α kinase-IN-5
<p>IRE1α kinase-IN-5 (compound 7) is a potent inhibitor of IRE1α (Ki: 98 nM) and is an ATP-competitive ligand for IRE1α.</p>Fórmula:C28H30N6O3SCor e Forma:SolidPeso molecular:530.643'-Deoxy-GTP
CAS:<p>3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate) is an analog of GTP and serves as an RNA chain terminator, effectively inhibiting RNA synthesis. It can inhibit dengue virus DENV NS5 RdRp with an IC50 of 0.02 μM.</p>Fórmula:C10H16N5O13P3Cor e Forma:SolidPeso molecular:507.1815-Fluorouridine 5'-phosphate
CAS:<p>5-Fluorouridine 5'-phosphate acts as an ODCase (uridine 5'-monophosphate decarboxylase) inhibitor, exhibiting a Ki value of 98 µM for human ODCase and 645 µM for Methanococcus jannaschii ODCase. This compound also shows inhibitory activity on leukemia and lymphoma cell lines, making it useful for cancer research studies.</p>Fórmula:C9H12FN2O9PCor e Forma:SolidPeso molecular:342.172Norharmine
CAS:<p>Norharmine is an analogue of harman and functions as an alkaloid. It serves as an inhibitor of both monoamine oxidase A (MAO-A) and DYRK1A. While it exhibits weak inhibitory activity against MAO-A, it has certain inhibitory effects on DYRK1A.</p>Fórmula:C12H10N2OCor e Forma:SolidPeso molecular:198.221IXA62
CAS:<p>IXA62 is an orally active, selective IRE1/XBP1s agonist (EC50= 0.31 μM) that can reduce Aβ secretion.</p>Fórmula:C24H23N3O3Cor e Forma:SolidPeso molecular:401.458HNC-1664
CAS:<p>HNC-1664 is an orally active inhibitor of RNA-dependent RNA polymerase (RdRP). It exhibits broad-spectrum antiviral activity against coronaviruses, including SARS-CoV-2 wild type and its variants (XBB.1.18, HK.3.1, BF.7.14, BA.1, HCoV-229E, HCoV-OC43), as well as arenaviruses. HNC-1664 also demonstrates anti-infective efficacy in a mouse model infected with the SARS-CoV-2 Delta variant.</p>Fórmula:C12H13FIN3O3Cor e Forma:SolidPeso molecular:393.153CDK1-IN-4
<p>CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.</p>Fórmula:C26H24ClN5SCor e Forma:SolidPeso molecular:474.02Dyrk1A/α-synuclein-IN-2
<p>Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual inhibitor of Dyrk1A and α-synuclein aggregation that acts on α-synuclein (IC50: 7.8 μM).</p>Fórmula:C21H16N4O4SCor e Forma:SolidPeso molecular:420.44LNA-GMP
CAS:<p>LNA-GMP, a nucleotide analogue, is utilized in the synthesis of oligonucleotides.</p>Fórmula:C11H14N5O8PCor e Forma:SolidPeso molecular:375.23CDK2-IN-31
CAS:<p>CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.</p>Fórmula:C37H52N6O5Cor e Forma:SolidPeso molecular:660.85Anticancer agent 29
<p>Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).</p>Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81BET/Aurora kinase-IN-1
CAS:<p>BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.</p>Fórmula:C25H30FN7OCor e Forma:SolidPeso molecular:463.55RAD51-IN-6
CAS:<p>RAD51-IN-6, a potent RAD51 gene inhibitor, may help research mitochondrial disorders. (WO2021164746A1, cmpd 23)</p>Fórmula:C27H40N3O5PSCor e Forma:SolidPeso molecular:549.66Glycyl H-1152 hydrochloride
CAS:<p>Glycyl-H-1152 is a potent ROCK-II inhibitor (IC50=11.8 nM) with high selectivity over CaMKII, PKG, Aurora A, PKA, and PKC. Better than Y-27632 and HA-1077.</p>Fórmula:C18H26Cl2N4O3SCor e Forma:SolidPeso molecular:449.39KI-CDK9d-32
CAS:<p>KI-CDK9d-32 is a CDK9 PROTAC degrader with a DC50 of 0.89 nM. It facilitates the ubiquitination and degradation of CDK9, inhibits the MYC pathway, and disrupts nucleolar homeostasis. KI-CDK9d-32 demonstrates anticancer activity.</p>Fórmula:C39H45N9O4Cor e Forma:SolidPeso molecular:703.83BBI-355
CAS:<p>BBI-355 is an oral, potent, and selective small molecule CHK1 inhibitor with an IC50 of 0.3 nM. It exhibits significant antitumor activity, both as a monotherapy and in combination with targeted therapies, across various ecDNA+ oncogene-amplified tumor models.</p>Fórmula:C19H19N7O2Cor e Forma:SolidPeso molecular:377.40Haspin-IN-2
CAS:<p>Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).</p>Fórmula:C12H8N4O3Cor e Forma:SolidPeso molecular:256.22Fradafiban
CAS:<p>Fradafiban binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb/IIIa antagonist.</p>Fórmula:C20H21N3O4Pureza:98%Cor e Forma:SolidPeso molecular:367.402'-F-UMP
CAS:<p>2'-F-UMP is a nucleotide analogue used in the synthesis of oligonucleotides.</p>Fórmula:C9H12FN2O8PPeso molecular:326.176-B345TTQ
CAS:<p>6-B345TTQ is an α4 integrin inhibitor that can impede the interaction between α4 and Leupaxin. This compound is applicable for studies focused on inflammation research.</p>Fórmula:C22H20BrNO4Cor e Forma:SolidPeso molecular:442.303Galidesivir
CAS:<p>Galidesivir (BCX4430) is an antiviral compound that inhibits viral RNA-dependent RNA polymerase (RdRp) activity and reduces lung infections in infected animals.</p>Fórmula:C11H15N5O3Pureza:96.73% - 99.13%Cor e Forma:SolidPeso molecular:265.27Des-ethyl-carafiban
CAS:<p>Des-ethyl-carafiban (Compound 44) is an antagonist of the fibrinogen receptor, effectively inhibiting platelet aggregation induced by various agonists. It is useful for research in thrombotic diseases.</p>Fórmula:C22H23N5O5Cor e Forma:SolidPeso molecular:437.4482′-O-MOE-AMP
CAS:<p>2′-O-MOE-AMP is a nucleotide analogue used in the synthesis of oligonucleotides.</p>Fórmula:C13H20N5O8PCor e Forma:SolidPeso molecular:405.30CDK4/6-IN-13
CAS:<p>Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.</p>Fórmula:C25H29N7OCor e Forma:SolidPeso molecular:443.54Aurora B inhibitor 1
CAS:<p>Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 uM) with potential anticancer activity for cancer research.</p>Fórmula:C25H26ClF2N7O2Pureza:98.37%Cor e Forma:SolidPeso molecular:529.97PD-1/PD-L1-IN-53
CAS:<p>PD-1/PD-L1-IN-53 (compound B3) serves as an inhibitor targeting both the PD-1/PD-L1 and VISTA signaling pathways. It is utilized in cancer research.</p>Fórmula:C31H37N3O4Cor e Forma:SolidPeso molecular:515.642'-F-AMP
CAS:<p>2'-F-AMP is a nucleotide analogue used in the synthesis of oligonucleotides.</p>Fórmula:C10H13FN5O6PPeso molecular:349.21CDK2-IN-30
CAS:<p>CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.</p>Fórmula:C18H25N7O3SCor e Forma:SolidPeso molecular:419.50LNA-UTP
CAS:<p>LNA-UTP is a nucleotide analogue used in the synthesis of oligonucleotides.</p>Fórmula:C10H15N2O15P3Cor e Forma:SolidPeso molecular:496.15BWC0977
CAS:<p>BWC0977 is an effective topoisomerase inhibitor that disrupts bacterial DNA replication by targeting both DNA gyrase and topoisomerase IV. The minimum inhibitory concentration (MIC90) of BWC0977 against MDR (multi-drug resistant) Gram-negative bacteria ranges from 0.03 to 2 µg/mL.</p>Fórmula:C22H21FN6O5Cor e Forma:SolidPeso molecular:468.44DYRK1-IN-1
CAS:<p>DYRK1-IN-1: Selective DYRK1A inhibitor with IC50 of 220 nM, good permeability, CNS penetrant for research, no P-glycoprotein issues.</p>Fórmula:C12H12N6Cor e Forma:SolidPeso molecular:240.26GSK3-IN-10
CAS:<p>GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.</p>Fórmula:C17H18F2N4O3Cor e Forma:SolidPeso molecular:364.347Antitumor agent-74
<p>Antitumor agent-74, a quinazoline derivative, inhibits DNA, arrests cell cycle, and induces apoptosis with agent-75.</p>Fórmula:C26H23FN6Cor e Forma:SolidPeso molecular:438.5Pseudouridine 5'-OTBDPS
CAS:<p>Pseudouridine5'-OTBDPS [5-(5-O-TBDPS-β-D-ribofuranosyl)uracil] is an intermediate of Pseudouridine.</p>Fórmula:C25H30N2O6SiCor e Forma:SolidPeso molecular:482.60N6-Benzoyl-2'-deoxy-3'-O-DMT-adenosine
CAS:<p>N6-Benzoyl-2'-deoxy-3'-O-DMT-adenosine is a nucleoside analog that resembles the natural nucleotide adenosine in structure. It acts as an activator of ribonucleotide reductase, facilitating the conversion of ribonucleotides into deoxyribonucleotides.</p>Fórmula:C38H35N5O6Cor e Forma:SolidPeso molecular:657.714RNAP-σ interaction inhibitor-1
CAS:<p>RNAP-σ interaction inhibitor-1 (compound 5d) acts as an inhibitor of the interaction between RNA polymerase and the sigma factor. It exhibits activity against Streptococci with a minimum inhibitory concentration (MIC) ranging from 1-2 µg/mL.</p>Fórmula:C19H11Cl3N2O6S2Cor e Forma:SolidPeso molecular:533.79BRD4 Inhibitor-40
CAS:<p>BRD4 Inhibitor-40 (Compound 23) functions as an inhibitor of BRD, effectively targeting BRD4-BD1, BRD4-BD2, BRD2-BD1, and BRD2-BD2, with IC50 values of 16.1, 142.18, 29.35, and 302.35 nM, respectively. It modulates the expression of c-Myc and p21, induces cell cycle arrest in the G1 phase, and inhibits Pkd1-deficient (PN) renal cystic epithelial cells. Additionally, it prevents renal cyst formation in both Madin-Darby canine kidney and embryonic kidney cyst models, and demonstrates renal cyst inhibition activity in mouse models.</p>Fórmula:C27H32N8OCor e Forma:SolidPeso molecular:484.596Aurora inhibitor 1
CAS:<p>Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).</p>Fórmula:C23H25N9SPureza:98%Cor e Forma:SolidPeso molecular:459.57FR-β ligand 1
CAS:<p>FR-β ligand 1 (III) is a ligand that specifically targets folate receptors, exhibiting antitumor activity, high selectivity, and strong affinity.</p>Fórmula:C22H25N5O6Cor e Forma:SolidPeso molecular:455.46DNA Gyrase-IN-16
CAS:<p>DNA Gyrase-IN-16 (Compound 9) is an inhibitor of DNA gyrase, with an IC50 of 1.609 μM. It exhibits antibacterial properties, effectively inhibiting S. aureus and MRSA, with a MIC of 3.125 μM for both.</p>Fórmula:C17H15N3O3Cor e Forma:SolidPeso molecular:309.319MY05
CAS:<p>MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).</p>Fórmula:C19H11ClN4OCor e Forma:SolidPeso molecular:346.77Anticancer agent 30
<p>Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.</p>Fórmula:C22H15ClFNOCor e Forma:SolidPeso molecular:363.81TA-316
CAS:<p>Agent induces megakaryocytes/platelets from stem cells to treat thrombopenia.</p>Fórmula:C28H25BrN4O5S2Pureza:98%Cor e Forma:SolidPeso molecular:641.56CDK4-IN-1
CAS:<p>CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50</p>Fórmula:C22H29ClN8Pureza:98%Cor e Forma:SolidPeso molecular:440.97SGC-CLK-1
CAS:<p>SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.</p>Fórmula:C19H15F3N6O2Cor e Forma:SolidPeso molecular:416.36MTH1 activator-1
CAS:<p>MTH1 activator-1 is an MTH1 activator that enhances endogenous MTH1 activity and significantly reduces 8-oxo-dG levels in cellular DNA. It is useful for investigating the upregulation of oxidative damage repair in nucleotide pools and examining biological effects, as well as for studies aiming to delay or prevent tumorigenesis.</p>Fórmula:C29H23F3N4O2Cor e Forma:SolidPeso molecular:516.514
